MedPath

Zidovudine

Generic Name
Zidovudine
Brand Names
Combivir, Retrovir, Trizivir
Drug Type
Small Molecule
Chemical Formula
C10H13N5O4
CAS Number
30516-87-1
Unique Ingredient Identifier
4B9XT59T7S

Overview

A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]

Background

A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]

Indication

Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.

Associated Conditions

  • HIV Transmission
  • Human Immunodeficiency Virus (HIV) Infections
  • Perinatal HIV transmission

FDA Approved Products

COMBIVIR
Manufacturer:H.J. Harkins Company, Inc.
Route:ORAL
Strength:300 mg in 1 1
Approved: 2012/02/02
NDC:52959-546
Zidovudine
Manufacturer:Cipla Ltd.
Route:ORAL
Strength:100 mg in 1 1
Approved: 2018/11/29
NDC:53104-0100
zidovudine
Manufacturer:Cipla Ltd.
Route:ORAL
Strength:50 mg in 5 mL
Approved: 2018/11/27
NDC:53104-0105
LAMIVUDINE and ZIDOVUDINE
Manufacturer:Bryant Ranch Prepack
Route:ORAL
Strength:300 mg in 1 1
Approved: 2022/01/27
NDC:71335-0639
RETROVIR
Manufacturer:ViiV Healthcare Company
Route:ORAL
Strength:10 mg in 1 mL
Approved: 2020/11/05
NDC:49702-212

Singapore Approved Products

APO-ZIDOVUDINE CAPSULE 100 mg
Manufacturer:APOTEX INC
Form:CAPSULE
Strength:100 mg
Online:Yes
Approved: 1993/05/24
Approval:SIN07438P
RETROVIR ORAL SOLUTION 10 mg/ml
Manufacturer:Bora Pharmaceutical Services Inc.
Form:SYRUP
Strength:10 mg/ml
Online:Yes
Approved: 1993/10/26
Approval:SIN07527P
COMBIVIR TABLETS
Manufacturer:Glaxo Operations UK Ltd (Trading as Glaxo Wellcome Operations), Delpharm Poznan S.A.
Form:TABLET, FILM COATED
Strength:300 mg
Online:Yes
Approved: 1999/03/09
Approval:SIN10795P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath